Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Etienne Khoury, Diane Brisson & Daniel Gaudet. (2020) Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia. Expert Opinion on Drug Discovery 15:4, pages 403-414.
Read now
Read now
Slobodan M. Janković, Danka Tešić, Jelena Anđelković & Marina Kostić. (2018) Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review. Expert Review of Pharmacoeconomics & Outcomes Research 18:5, pages 461-474.
Read now
Read now
Courtney A Henry, Ronald A Lyon & Hua Ling. (2016) Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction. Vascular Health and Risk Management 12, pages 163-169.
Read now
Read now
Alessandro Colletti, Giuseppe Derosa & Arrigo FG Cicero. (2016) Retargeting the management of hypercholesterolemia – focus on evolocumab. Therapeutics and Clinical Risk Management 12, pages 1365-1376.
Read now
Read now
Articles from other publishers (12)
Ezgi Dayar & Olga Pechanova. (2022) Targeted Strategy in Lipid-Lowering Therapy. Biomedicines 10:5, pages 1090.
Crossref
Crossref
Pratik Pandey, Cuimei Zhao & Ban Liu. 2020. Precision Medicine. Precision Medicine
133
143
.
Allison B. ReissNeal ShahDalia MuhieddineJuan ZhenJennifer YudkevichLora J. KasselmanJoshua DeLeon. (2018) PCSK9 in cholesterol metabolism: from bench to bedside. Clinical Science 132:11, pages 1135-1153.
Crossref
Crossref
Mita Kuchimanchi, Anita Grover, Maurice G. Emery, Ransi Somaratne, Scott M. Wasserman, John P. Gibbs & Sameer Doshi. (2018) Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia. Journal of Pharmacokinetics and Pharmacodynamics 45:3, pages 505-522.
Crossref
Crossref
Dhrubajyoti Bandyopadhyay, Kumar Ashish, Adrija Hajra, Arshna Qureshi & Raktim K. Ghosh. (2018) Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering. Journal of Lipids 2018, pages 1-13.
Crossref
Crossref
R. Khatib & F. Wilson. 2018. Encyclopedia of Cardiovascular Research and Medicine. Encyclopedia of Cardiovascular Research and Medicine
68
88
.
R. Khatib. 2018. Reference Module in Biomedical Sciences. Reference Module in Biomedical Sciences.
Massimiliano Ruscica, Nicola Ferri, Federica Fogacci, Martina Rosticci, Margherita Botta, Silvia Marchiano, Paolo Magni, Sergio D'Addato, Marina Giovannini, Claudio Borghi, Arrigo F. G. Cicero, Martino Morbini, Enrico Bertagnin, Elisa Grandi, Silvia Palmesano, Elisabetta Rizzoli, Riccardo Urso, Giuseppe Derosa & Stefano Bacchelli. (2017) Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study. Journal of the American Heart Association 6:5.
Crossref
Crossref
Rahul Chaudhary, Jalaj Garg, Neeraj Shah & Andrew Sumner. (2017) PCSK9 inhibitors: A new era of lipid lowering therapy. World Journal of Cardiology 9:2, pages 76.
Crossref
Crossref
Amirhosssein Sahebkar, Željko Reiner, Luis E. Simental-Mendía, Gianna Ferretti & Arrigo F.G. Cicero. (2016) Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. Metabolism 65:11, pages 1664-1678.
Crossref
Crossref
Chanukya Dahagam, Aditya Goud, Abdelhai Abdelqader, Aditya Hendrani, Matthew J Feinstein, Arman Qamar, Parag H Joshi, Kristopher J Swiger, Kathleen Byrne, Renato Quispe, Steven R Jones, Roger S Blumenthal & Seth S Martin. (2016) PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab. Future Cardiology 12:2, pages 139-148.
Crossref
Crossref
I. Ramasamy. (2016) Update on the molecular biology of dyslipidemias. Clinica Chimica Acta 454, pages 143-185.
Crossref
Crossref